Once-Weekly Semaglutide in Adults With Daily Cigarette Use
JAMA Network Open · 26.05.2026 · 9 (5) · e2614898
DOI: 10.1001/jamanetworkopen.2026.14898 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 26.05.2026. Verfasst von Christian S Hendershot und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Cigarette Smoking, Smoking Cessation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance People who smoke cigarettes face increased risk of morbidity and mortality, in part due to elevated rates of cardiometabolic disease. Preclinical and early clinical data indicate that glucagon-like peptide-1 receptor agonists (GLP-1RAs) warrant consideration for smoking cessation and prevention of associated cardiometabolic risks.
Objective
To evaluate the effects of semaglutide vs placebo on cigarette smoking, craving, and weight outcomes in people who smoke. Design, Setting, and Participants This parallel-arm phase 2a randomized clinical trial with embedded human laboratory sessions was conducted at an academic medical center, with enrollment occurring from October 2022 to April 2024. Participants were non–treatment-seeking adults consuming at least 5 cigarettes per day. Data were analyzed in 2025.
Intervention
Nine weeks of subcutaneous of semaglutide (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week) vs placebo. Main Outcomes and Measures The co–primary outcomes were laboratory measures of smoking resistance and reinstatement and self-administration, assessed before and after treatment. Changes in cigarette use, cigarette craving, body weight, and other outcomes were assessed weekly.
Results
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the primary outcome assessment. Primary treatment-by-time interactions on laboratory measures of smoking resistance (23 participants; β = 0.16 [95% CI, −0.07 to 0.40]; P = .16) and number of cigarettes (22 participants; β = −0.08 [95% CI, −0.25 to 0.08]; P = .30) were not significant. Supplementary change score analyses indicated significantly greater reductions in laboratory smoking (β = −0.69 [95% CI, −1.26 to −0.13]; P = .02; d = 0.67) in the semaglutide group vs the placebo group after treatment. Semaglutide reduced cigarette craving (treatment-by-time interaction: β = −0.11 [95% CI, −0.20 to −0.03]; P = .01) and body weight (β = −0.04 [95% CI, −0.05 to −0.03]; P < .001) over treatment weeks. Exploratory effect size analyses indicated potential effects on withdrawal symptoms. Conclusions and Relevance In this phase 2a randomized clinical trial, semaglutide monotherapy did not significantly increase laboratory smoking resistance or reduce weekly cigarettes per day but reduced nicotine craving and body weight. Larger trials should evaluate effects of GLP-1RA therapies on cessation, postcessation weight gain, and cardiometabolic outcomes in people who smoke. Trial Registration ClinicalTrials.gov Identifier: NCT05530577
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles.
- Institute for Addiction Science, Keck School of Medicine, University of Southern California, Los Angeles.
- Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles.
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill.
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill.
- Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill.
Förderung
- NCATS NIH HHS
Zitieren
APA
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Prince, M. A., Dermody, S. S., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2026). Once-Weekly Semaglutide in Adults With Daily Cigarette Use. JAMA Network Open, 9(5), e2614898. https://doi.org/10.1001/jamanetworkopen.2026.14898
Vancouver
Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use. JAMA Network Open. 2026;9(5):e2614898. doi:10.1001/jamanetworkopen.2026.14898
BibTeX
@article{Hendershot2026,
author = {Hendershot, Christian S and Bremmer, Michael P and Paladino, Michael B and Kostantinis, Georgios and Gilmore, Thomas A and Sullivan, Neil R and Tow, Amanda C and Prince, Mark A and Dermody, Sarah S and Jordan, Robyn and McKee, Sherry A and Fletcher, Paul J and Claus, Eric D and Klein, Klara R},
title = {Once-Weekly Semaglutide in Adults With Daily Cigarette Use},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {5},
pages = {e2614898},
doi = {10.1001/jamanetworkopen.2026.14898}
}
EUVIMED